We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: mHSPC
MedXY News
EnglishTag

mHSPC

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Dual Blockade of AKT and AR Pathways: Capivasertib Plus Abiraterone Significantly Extends rPFS in PTEN-Deficient mHSPC
newsmHSPConcology

Dual Blockade of AKT and AR Pathways: Capivasertib Plus Abiraterone Significantly Extends rPFS in PTEN-Deficient mHSPC

By MedXY|Jan 9, 2026

The CAPItello-281 trial shows that capivasertib plus abiraterone improves radiographic progression-free survival by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer, highlighting the importance of biomarker-driven t

Evolving Treatment Patterns and Survival Outcomes in Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer
newsandrogen receptor pathway inhibitorscombination therapy
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Evolving Treatment Patterns and Survival Outcomes in Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer

By MedXY|Oct 30, 2025

A retrospective study in US veterans reveals increased use of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), showing improved survival over ADT alone. ARPIs and docetaxel demonstrate comparable overall survi

Age-Dependent Benefits of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Meta-Analysis
newsandrogen receptor pathway inhibitorschemotherapy

Age-Dependent Benefits of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Meta-Analysis

By MedXY|Oct 30, 2025

This meta-analysis reveals that systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, with greater benefits in younger men and nuanced effects in older men, especially based on disease

Optimizing Therapy for Older Patients with Metastatic Hormone-Sensitive Prostate Cancer: Insights from a Network Meta-Analysis of Doublet versus Triplet Regimens
newsdarolutamidemetastatic hormone-sensitive prostate cancer

Optimizing Therapy for Older Patients with Metastatic Hormone-Sensitive Prostate Cancer: Insights from a Network Meta-Analysis of Doublet versus Triplet Regimens

By MedXY|Oct 30, 2025

This network meta-analysis reveals that triplet therapy with darolutamide, ADT, and docetaxel offers the greatest overall survival benefit for older patients with metastatic hormone-sensitive prostate cancer, highlighting the need to balanc

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities